Exploring Cognitive and Neuroimaging Profiles of Dementia Subtypes of Individuals with Dementia in the Democratic Republic of Congo DOI
Jean Ikanga, Saranya Sundaram, Megan Schwinne

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 18, 2024

ABSTRACT Objective The 2024 Alzheimer’s Association (AA) research diagnostic criteria for Disease (AD) considers fluid biomarkers, including promising blood-based biomarkers detecting AD. This study aims to identify dementia subtypes and their cognitive neuroimaging profiles in older adults with the Democratic Republic of Congo (DRC) using clinical data. Methods Forty-five individuals over 65 years old were evaluated Community Screening Instrument Dementia informant-based Questionnaire. Core AD (Aβ42/40 p-tau181) non-specific neurodegeneration (NfL, GFAP) measured blood plasma. Neuroimaging structures assessed magnetic resonance imaging (MRI). determined based on plasma biomarker pathology vascular markers. Biomarker cutoff scores identified optimize sensitivity specificity. Individuals stratified into one four – only, non-AD vascular, other, or mixed combinations abnormalities these Results Among 45 dementia, had highest prevalence (42.4%), followed by AD-only (24.4%), other (22.2%), (11.1%). Both aligned poorly classifications full sample. Cognitive tests varied across subtypes. profile groups suggested relatively low performance, while best average. Conclusion Consistent studies settings, our preliminary findings suggest that neurodegenerative may help provide insight among DRC.

Language: Английский

The Potential of cfDNA as Biomarker: Opportunities and Challenges for Neurodegenerative Diseases DOI Creative Commons
Şeyma Aydın, Selçuk Özdemir, Ahmet Adıgüzel

et al.

Journal of Molecular Neuroscience, Journal Year: 2025, Volume and Issue: 75(1)

Published: March 13, 2025

Abstract Neurodegenerative disorders, including Alzheimer’s disease (AD), Parkinson’s (PD), multiple sclerosis (MS), and amyotrophic lateral (ALS), are characterized by the progressive gradual degeneration of neurons. The prevalence rates these disorders rise significantly with age. As life spans continue to increase in many countries, number cases is expected grow foreseeable future. Early precise diagnosis, along appropriate surveillance, continues pose a challenge. high heterogeneity neurodegenerative diseases calls for more accurate definitive biomarkers improve clinical therapy. Cell-free DNA (cfDNA), fragmented released into bodily fluids via apoptosis, necrosis, or active secretion, has emerged as promising non-invasive diagnostic tool various diseases. cfDNA can serve an indicator ongoing cellular damage mortality, neuronal loss, may provide valuable insights processes, progression, therapeutic responses. This review will first cover key aspects then examine recent advances its potential use biomarker disorders.

Language: Английский

Citations

1
Blood-Based Biomarkers in Alzheimer’s Disease: Advancing Non-Invasive Diagnostics and Prognostics DOI Open Access
Mrinmay Dhauria, Ritwick Mondal, Shramana Deb

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(20), P. 10911 - 10911

Published: Oct. 10, 2024

Alzheimer’s disease (AD), the most prevalent form of dementia, is expected to rise dramatically in incidence due global population aging. Traditional diagnostic approaches, such as cerebrospinal fluid analysis and positron emission tomography, are expensive invasive, limiting their routine clinical use. Recent advances blood-based biomarkers, including amyloid-beta, phosphorylated tau, neurofilament light, offer promising non-invasive alternatives for early AD detection monitoring. This review synthesizes current research on these highlighting potential track pathology enhance accuracy. Furthermore, this uniquely integrates recent findings protein-protein interaction networks microRNA pathways, exploring novel combinations proteomic, genomic, epigenomic biomarkers that provide new insights into AD’s molecular mechanisms. Additionally, we discuss integration with advanced neuroimaging techniques, emphasizing revolutionize diagnostics. Although large-scale validation still needed, represent a critical advancement toward more accessible, cost-effective, tools AD.

Language: Английский

Citations

4
Older US adults’ experiences with and views about cognitive screening and blood biomarker testing for Alzheimer's disease DOI Creative Commons

Chelsea G. Cox,

Matthias Kirch, Dianne Singer

et al.

Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring, Journal Year: 2025, Volume and Issue: 17(1)

Published: Jan. 1, 2025

Language: Английский

Citations

0
Exploring the ability of plasma pTau217, pTau181 and beta-amyloid in mirroring cerebrospinal fluid biomarker profile of Mild Cognitive Impairment by the fully automated Lumipulse® platform DOI Creative Commons
Marcella Catania,

Claudia Battipaglia,

Alberto Perego

et al.

Fluids and Barriers of the CNS, Journal Year: 2025, Volume and Issue: 22(1)

Published: Jan. 21, 2025

The approval of new disease-modifying therapies by the U.S. Food and Drug Administration European Medicine Agency makes it necessary to optimize non-invasive cost-effective tools for identification subjects at-risk developing Alzheimer's Disease (AD). Plasma biomarkers are excellent candidates. However, their ability reflect cerebrospinal fluid (CSF) profile - that remains date gold standard biochemical diagnosis AD needs be confirmed validated before implementation in clinical practice. aims this study analyse correlation between CSF plasma Aβ40, Aβ42, Aβ42/Aβ40 pTau181, assess diagnostic performance a cohort affected Mild Cognitive Impairment (MCI). was performed on 306 MCI, enrolled context Italian Interceptor Project. Aβ42 pTau181 were analysed CSF, pTau217 measured plasma. fully automated chemiluminescence enzyme immunoassay Lumipulse® G600II (Fujirebio) instrument used all measurements. We correlations differences biomarker concentrations after grouping MCI cases according AT classification profiles. found statistically significant positive ratio pTau181. All biomarkers, except showed A+ vs. A-, A+T+ A-T- A+T- patients. Moreover, levels lower compared A-T+ groups, higher A+T-. robust distinguishing from A- (AUC = 0.857 0.862, respectively) 0.866 0.911) subjects. Our results suggest especially pTau217, promising candidates early detection pathology.

Language: Английский

Citations

0
Detecting mild cognitive impairment by applying integrated random forest to finger tapping DOI
Yuko Sano, Shota Suzumura, Junpei Sugioka

et al.

Medical & Biological Engineering & Computing, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Exploring cognitive and neuroimaging profiles of dementia subtypes of individuals with dementia in the Democratic Republic of Congo DOI Creative Commons
Jean Ikanga, Saranya Sundaram, Megan Schwinne

et al.

Frontiers in Aging Neuroscience, Journal Year: 2025, Volume and Issue: 17

Published: Feb. 12, 2025

Objective The 2024 Alzheimer’s Association (AA) research diagnostic criteria for Disease (AD) considers fluid biomarkers, including promising blood-based biomarkers detecting AD. This study aims to identify dementia subtypes and their cognitive neuroimaging profiles in older adults with the Democratic Republic of Congo (DRC) using clinical data. Methods Forty-five individuals over 65 years old were evaluated Community Screening Instrument Dementia informant-based Questionnaire. Core AD (Aβ42/40 p-tau181) non-specific neurodegeneration (NfL, GFAP) measured blood plasma. Neuroimaging structures assessed magnetic resonance imaging (MRI). determined based on plasma biomarker pathology vascular markers. Biomarker cutoff scores identified optimize sensitivity specificity. Individuals stratified into one four subtypes—AD only, non-AD vascular, other, or mixed – combinations abnormalities these Results Among 45 dementia, had highest prevalence (42.4%), followed by AD-only (24.4%), other (22.2%), (11.1%). Both aligned poorly classifications full sample. Cognitive tests varied across subtypes. profile groups suggested relatively low performance, while best average. Conclusion Consistent studies settings, our preliminary findings suggest that neurodegenerative may help provide insight among DRC.

Language: Английский

Citations

0
Longitudinal Evaluation of the Detection Potential of Serum Oligoelements Cu, Se and Zn for the Diagnosis of Alzheimer’s Disease in the 3xTg-AD Animal Model DOI Open Access
Olívia Furiama Metropolo Dias, Nicole M. E. Valle, Javier Bustamante Mamani

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(8), P. 3657 - 3657

Published: April 12, 2025

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of β-amyloid (Aβ) and hyperphosphorylated tau, leading to neuroinflammation, oxidative stress, neuronal death. Early detection AD remains challenge, as clinical manifestations only emerge in advanced stages, limiting therapeutic interventions. Minimally invasive biomarkers are essential for early identification monitoring progression. This study aims evaluate sensitivity relationship between serum oligoelement levels progression 3xTg-AD model. Transgenic mice C57BL/6 controls were evaluated over 12 months through quantification using inductively coupled plasma mass spectrometry (ICP-MS), Aβ deposition via immunohistochemistry, cognitive assessments memory tests (Morris water maze novel object recognition test), well spontaneous locomotion analysis open field test. The results demonstrated that oligoelements (copper, zinc, selenium) sensitive detecting alterations group, preceding motor deficits. Immunohistochemistry was performed qualitative purposes, confirming presence CNS transgenic animals. Up third month, labeling moderate restricted cell bodies; from fifth month onward, evident extracellular deposits emerged. Behavioral assessment indicated impairments spatial episodic memory, altered locomotor patterns mice. These findings reinforce variations may be associated with processes, including stress synaptic dysfunction. Thus, emerges promising approach diagnosis progression, potentially contributing development new strategies.

Language: Английский

Citations

0
TOMM40 may mediate GFAP, neurofilament light Protein, pTau181, and brain morphometry in aging DOI Creative Commons
Robyn A. Honea, Heather Wilkins, Suzanne Hunt

et al.

Aging Brain, Journal Year: 2024, Volume and Issue: 7, P. 100134 - 100134

Published: Dec. 13, 2024

Language: Английский

Citations

1
Exploring Cognitive and Neuroimaging Profiles of Dementia Subtypes of Individuals with Dementia in the Democratic Republic of Congo DOI
Jean Ikanga, Saranya Sundaram, Megan Schwinne

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 18, 2024

ABSTRACT Objective The 2024 Alzheimer’s Association (AA) research diagnostic criteria for Disease (AD) considers fluid biomarkers, including promising blood-based biomarkers detecting AD. This study aims to identify dementia subtypes and their cognitive neuroimaging profiles in older adults with the Democratic Republic of Congo (DRC) using clinical data. Methods Forty-five individuals over 65 years old were evaluated Community Screening Instrument Dementia informant-based Questionnaire. Core AD (Aβ42/40 p-tau181) non-specific neurodegeneration (NfL, GFAP) measured blood plasma. Neuroimaging structures assessed magnetic resonance imaging (MRI). determined based on plasma biomarker pathology vascular markers. Biomarker cutoff scores identified optimize sensitivity specificity. Individuals stratified into one four – only, non-AD vascular, other, or mixed combinations abnormalities these Results Among 45 dementia, had highest prevalence (42.4%), followed by AD-only (24.4%), other (22.2%), (11.1%). Both aligned poorly classifications full sample. Cognitive tests varied across subtypes. profile groups suggested relatively low performance, while best average. Conclusion Consistent studies settings, our preliminary findings suggest that neurodegenerative may help provide insight among DRC.

Language: Английский

Citations

0